glp 1 for chronic kidney disease RACGP Glucagon-Like Peptide-1 Receptor Agonist Use

8.7 Hepatic Impairment The recommended dosage in patients with hepatic impairment is the same as those with normal hepatic function

Pros and Cons at a Glance GLP-1s Big, fast weight loss Improves heart outcomes in high-risk patients Suppresses appetite Side effects & high cost Risk of muscle/bone loss More loose skin with rapid loss Exercise Improves health & lifespan even without weight loss Builds muscle and bone Low risk, low cost Builds lifelong habits Slower weight loss The Best of Both Worlds It doesnt have to be either/or

These divergent findings likely reflect heterogeneity in study design, mechanisms of action of the drugs evaluated, duration of follow-up, and the degree of metabolic phenotyping across populations

BPC-157 in Animal Studies: Promising but Preliminary Multiple preclinical studies have shown encouraging findings: Tendon and ligament healing : Animal models suggest faster recovery after surgical repairs or experimental ruptures ([1], [2])

At this time, I currently do not recommend my patients take BPC 157